Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
United States
/
Pharmaceuticals & Biotech
/
Esperion Therapeutics
ESPR
Esperion Therapeutics
Regulatory Pressures And Fierce Competition Will Compress Margins
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 7 Analysts
Published
28 Aug 25
Updated
28 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$1.60
38.1% overvalued
intrinsic discount
28 Aug
US$2.21
1Y
26.3%
7D
3.8%
Loading
1Y
26.3%
7D
3.8%
Author's Valuation
US$1.6
38.1% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$1.6
38.1% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-308m
337m
2014
2017
2020
2023
2025
2026
2028
Revenue US$337.0m
Earnings US$78.3m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
14.87%
Pharma revenue growth rate
0.57%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.32%
Calculation
US$78.25m
Earnings '28
x
5.46x
PE Ratio '28
=
US$427.15m
Market Cap '28
US$427.15m
Market Cap '28
/
216.04m
No. shares '28
=
US$1.98
Share Price '28
US$1.98
Share Price '28
Discounted to 2025 @ 7.32% p.a.
=
US$1.60
Fair Value '25
